Shares of Smith & Nephew plc (LON:SN) have received an average recommendation of “Hold” from the fourteen ratings firms that are covering the company. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is GBX 1,308.18 ($17.08).
SN has been the subject of several research reports. Numis Securities Ltd restated an “add” rating and set a GBX 1,242 ($16.21) price objective on shares of Smith & Nephew plc in a research note on Friday, June 24th. Berenberg Bank lifted their price objective on shares of Smith & Nephew plc from GBX 1,300 ($16.97) to GBX 1,485 ($19.38) and gave the company a “buy” rating in a research note on Tuesday, July 12th. Jefferies Group restated a “buy” rating and set a GBX 1,375 ($17.95) price objective on shares of Smith & Nephew plc in a research note on Thursday, June 9th. Goldman Sachs Group Inc. decreased their price objective on shares of Smith & Nephew plc from GBX 1,410 ($18.40) to GBX 1,370 ($17.88) and set a “buy” rating for the company in a research note on Tuesday, August 2nd. Finally, Barclays PLC cut shares of Smith & Nephew plc to an “equal weight” rating and lifted their price objective for the company from GBX 1,230 ($16.06) to GBX 1,240 ($16.19) in a research note on Wednesday, August 10th.
In other Smith & Nephew plc news, insider Bottomley ,Virginia bought 238 shares of the company’s stock in a transaction dated Monday, August 15th. The stock was acquired at an average price of GBX 1,290 ($16.84) per share, with a total value of £3,070.20 ($4,007.57).
Smith & Nephew plc (LON:SN) traded up 0.97% during trading on Wednesday, reaching GBX 1252.00. 1,561,673 shares of the company’s stock traded hands. Smith & Nephew plc has a one year low of GBX 1,040.36 and a one year high of GBX 1,324.00. The company has a 50-day moving average price of GBX 1,244.89 and a 200 day moving average price of GBX 1,202.77. The firm’s market capitalization is GBX 11.19 billion.
About Smith & Nephew plc
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. The Company offers various product franchises, which include Knee implants, Hip implants, Sports Medicine Joint Repair, Arthroscopy Enabling Technologies, Trauma and Extremities, Other Surgical Businesses, Advanced Wound Care, Advanced Wound Devices and Advanced Wound Bioactives.
Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with MarketBeat.com's FREE daily email newsletter.